Marizyme, Inc.

Marizyme, Inc. is a biomedical company specializing in the development and commercialization of medical technologies for vascular preservation and protection. The company is best known for DuraGraft®, the first and only FDA-cleared solution designed for the flushing and storage of saphenous vein grafts during Coronary Artery Bypass Grafting (CABG) procedures. DuraGraft is formulated to reduce oxidative damage during intraoperative storage, maintain cell viability, and preserve structural integrity of vein grafts. Clinical evidence demonstrates that saphenous vein grafts stored in DuraGraft exhibit significantly less wall thickening at 12 months post-CABG compared to those stored in saline. The company leverages proprietary enzyme technology and bioengineering expertise to address critical challenges in vascular graft preservation, offering solutions that improve patient outcomes in cardiothoracic surgery.